#44~ New "Post Dr." 4 XMRV & CFS & UK Research

ATTN: Please SHARE this Info with 

anyone you know that might be 

interested in This  Position..

....to Help us Study this, OK?


News fresh from the field.... 

Share ASAP!!!

Post Dr Assoc
Cornell University
Cornell University, located in Ithaca, 
New York, is an inclusive, dynamic, and 
innovative Ivy League university and New 
York's and-grant institution. Its staff, faculty, 
and students impart an uncommon sense 
of larger purpose and contribute creative 
ideas and best practices to further the 
university's mission of teaching,
research, and outreach.

The Department of Molecular Biology and 
Genetics seeks a postdoctoral research 
associate to study the role of the newly 
discovered retrovirus XMRV in chronic 
syndrome (CFS).  Blood from a cohort of 
CFS patients and controls in upstate 
New York will be examined for the presence
of virus, viral proteins, and antibodies to
viral proteins.  Sequences of XMRV from 
different patients will be obtained in order 
to characterize the diversity of viruses in 
the population.  Whether virus sequences 
correlate with functional status of CFS 
patients will be determined.  This project 
will be undertaken in collaboration with the 
Whittemore-Peterson Institute in Reno,
Nevada and the Columbia University Center 
for Infection and Immunity as well as with 
several physicians treating CFS patients.  
For more information regarding the 
Department of Molecular Biology and
Genetics, visit http://mbg.cornell. edu/.

Qualifications:
PhD degree in an area of Molecular Biology 
and/or Biochemistry or Virology.  
Prior experience with mammalian cell 
culture and/or retroviruses is desirable 
but not required.

Please send cover letter and CV with 
names of three references to 
Prof. Maureen Hanson, 
Dept of Molecular Biology and Genetics, 
323 Biotechnology Bldg., 
Cornell University, 
Ithaca, NY   14853 or to
cfs.study@gmail. com.  
Applications will be received for 
consideration until a suitable candidate 
is identified.

Cornell University is an equal opportunity, 
affirmative action educator and employer.

Job: Molecular Biology & Genetics
Primary Location: Ithaca
Requisition Number: 11845
Organization:  
Molecular Biology & Genetics - AG

~posted originally by~ 
 ***********************************
New Research FINALLY in the U.K...
but then Dr Peterson is in London <;-)))

ME Solutions and Invest in ME are
working together to maximize the
opportunities to fund research into
ME/CFS. The research project is -
The role of XMRV in modulation of NK
cell cytotoxicity and NK cell gene
abnormalities in ME/CFS patients and
normal blood donors.
The project will be carried out by
Dr Jonathan Kerr and his team from
St. George's University, London, and
Dr Amolak Bansal of the Department of
Immunology, Epsom & St Helier
University Hospitals NHS Trust.


Full article HERE

*gentle Hugs* and keep those Letters 
heading to your Ministers of Health or 
Congress, HHS, Surgeon General, or
whomever has Power in your Country, OK?

#37~ Mixed news about HEB lab-Ampligen

Many of us have been hearing about previous
ME/CFS patients on trials of Ampligen and some
have done incredibly well for long periods of time
after being on it for about 18 months and others
felt no improvement at all.

Recently, Hemispherix Labs (AMEX:HEB)
posted some news about new trials they
were about to start and at the same time
we have news about a class action suit
being brought against them for withholding
info about request for info that was not complete
that needed to be submitted to the FDA.

I will present both sets of info for you here to read.

Nov 10, 2009 
Dyer & Berens LLP (www.DyerBerens.com) today
announced that it has filed a class action lawsuit
in the United States District Court for the Eastern
District of Pennsylvania, Civil Action No. 09-cv-5262,
on behalf of all purchasers of the securities of 
Hemispherx Biopharma, Inc. 
("Hemispherx" or the "Company") (AMEX: HEB)
between February 18, 2009 and October 30, 2009 
(the "Class Period"), for violations of the federal
Securities Exchange Act of 1934.

The complaint alleges that, during the Class Period,

defendants misled investors regarding the status

of Hemispherx's New Drug Application ("NDA") 

for Ampligen with the U.S. Food and Drug 

Administration ("FDA"). Specifically, defendants 

failed to disclose and misrepresented the fact 

that the FDA had requested several reports 

from the Company before the NDA could even

be considered, thus delaying the possible 

approval of Ampligen by several months 

at a minimum. 

On November 2, 2009, when the Company 
belatedly disclosed this information, the per share
price of Hemispherx's common stock dropped
from $1.45 on the previous day to $1.13,
a drop of more than 20%. The next day,
one commenter characterized the November 2nd
Company "update" as essentially an admission
"that its prior public statements were
false and misleading."

Tuesday, November 2, 2009

Update from Hemispherx Biopharma 

(makers of Ampligen)

Hemispherx Biopharma Updates Chronic Fatigue 
Syndrome (CFS) Treatment and Commercial 
Application Programs

PHILADELPHIA, Nov. 2, 2009 (GLOBE NEWSWIRE)
-- Hemispherx Biopharma, Inc. (NYSE Amex:HEB)
(the "Company"), announced a two-prong CFS
clinical mission for November and December 2009.


The Company plans to widen its ongoing clinical
programs in CFS by accelerating collaborations
with a consortium of researchers who have just
discovered a retroviral link to
Chronic Fatigue Syndrome. A clinically validated
test to detect retrovirus antibodies in patients
plasma is also currently under development
(please see US National Institutes of Health ).

With the consortium of researchers at the
Whittemore Peterson Institute, the Company is
also now evaluating the defect in
immunosurveillance in specific subsets of
CFS patients in a clinical study entitled
"Therapeutic Activation of NK lymphocytes to
Alleviate Chronic Fatigue Syndrome."
These immune defects may be due
to the previously undetected retrovirus.

The Company also plans to complete all 

outstanding queries from the FDA regarding 

its New Drug Application (NDA) for Ampligen(R),

an experimental therapeutic, 

during November and December, 2009.

On May 26, 2009, the Company announced a delay
on the Ampligen NDA which, at the time, had a
PDUFA date of May 25, 2009. As noted in the
10-Q and 10-K filings at the time, the FDA did 

not request "additional information" from the 

Company at that time. However, several 

outstanding NDA items, requiring Hemispherx

responses, existed at the time of the FDA delay

as noted in the August 8, 2009, 10Q filing.
Between March 9, 2009 and September 15, 2009,
the Company issued six (6) new reports to the
Agency spanning various subjects including
a) clinical safety assessments,
b) specialized pre-clinical toxicology reports, and
c) abbreviated chemistry and manufacturing
control reports.
The Company believes that these reports may
fully retire all Agency queries in these
particular areas.


The Company also plans to submit four (4)
additional reports on interrelated topics in
November and December, 2009, which will
include pharmacokinetic analyses in multiple
lower animal species (primates, rodents, etc.)
("the Lovelace Laboratory Studies") and final
validation reports of certain manufacturing
procedures conducted at an independent facility,
Hollister-Stier Laboratories in Spokane, WA.
Some of these reports were recently cited in
BioMedReports.com and the
Science Business Exchange (October 15, 2009).

Information contained in this news release other

than historical information, should be considered 

forward-looking and is subject to various risk factors

and uncertainties.

The Company disclaims, however, any intent
or obligation to update these forward-looking 

statements. Clinical trials for other potential 

indications of the approved biologic 

Alferon N Injection® do not imply that the product

will ever be specifically approved commercially for

these other treatment indications;  

Similarly, the completion of NDA filing process

with Ampligen® does not imply that the product

will ever be approved commercially. 

"partial press release" reprinted from:

Hemispherix Biopharma website 

Personally as an investor that HAD owned HEB
during the time mentioned in the class action suit

I agree that HEB was NOT forth-coming with the

actual facts of the matter...However, as I was NOT
in for the "long haul" but the trade>had let the stock
"pop up">sold my holdings>made my profit, and
was a Happy Camper. I will NOT be participating
in the class action, however I had a feeling back 
then when I was reading their website and saw 
some weird changes being made that something 
was a bit "fishy" as they say...

Unfortunatley, in this day and age, whether you
are a patient or investor
the Same RULE applies:

"Caveat Emptor"

#19~ Recent "Spin Dr" papers published

Thought you might like to see some of 
the papers that have recently been 
published "AFTER" the NCI, CC, WPI 
paper were published about XMVR... 
So these seem to be papers published 
to counter the "new" NEWS Headlines...
and IMHO these papers are..well... 
you know.. what's the phrase??  FOS?


Here's one that deals with the whether 
the patients chosen had to be determined 
IF they had some other disease "actually"
besides ME/CFS ..and of course, done 
on "rural" folks, not those of us that are
highly education, type A-s that were 
leading Productive BUSY lives and NOT 
depressed and NOT are NOW, even with 
this sucky illness....

"NEED" I "bother" to state that Reeves 
is  part of these?????? nuff said....

http://www.biomedcentral.com/1741-7015/7/57

The 2nd one even goes MORE into the 
issue of whether there are Depressed 
Issues that need to be considered when 
dealing with CFS. IMHO... it is another 
re-directed  issue of "DENIAL" that needs 
to be addressed by these folks that 
"hand-pick" the patients that choose to 
interview, cuz maybe the ones that 
"KNOW the difference" & I, personally,
ReFUSE to deal with anything that 
includes Reeves in the title... 
always will... I don't give Private
Info to Spin Dr's that are in Denial 
and have already pro-conceived 
notions instead of remaining OPEN to 
the looking for NEW/REAL answers and 
"actively" looking for the TRUTH that 
contradictes the answers they 
Denied 25 years go..at Incline Village !



CDC do U need 2cents to "Get a Clue" ??

http://www.biomedcentral.com/1741-7015/7/58

NOT sure "IF" Enjoy is the correct 
word. However, please read these and 
let me know if I am way off base and
feel free to share your
comments, OK?


...and have a Great weekend where ever 
you are, and KNOW that YOU are NOT 
your illness and that you ARE "worth" 
MORE than the sum of your parts...
There IS a HUGE Group of us out here
that Support you... and we are NOT
Depressed, we are Angry at the Lack of 
Intelligent Research done by the CDC
over the last 25 years..and hurt by the 
denial and "choosing to mislabel" the 
28 million of us that have worked HARD
to stay SANE in the face of 
Federal Ignorance, by the Agency that
is charged with looking out for 
"OUR BEST INTEREST."

Can I Please request that those that 
have "not yet" signed the petition
for the CDC to "remove" the OLD
definition of CFS, please sign this
petition.....ASAP before the CFSAC
meeting Oct 29th !!! Please circulate
as much as you can, OK? *hugs*


CDC- "change the definition"



*cheers*